Aptevo Therapeutics Future Growth

Future criteria checks 0/6

Aptevo Therapeutics is forecast to grow earnings and revenue by 33.5% and 67.8% per annum respectively while EPS is expected to grow by 61.7% per annum.

Key information

33.5%

Earnings growth rate

61.7%

EPS growth rate

Biotechs earnings growth	27.3%
Revenue growth rate	67.8%
Future return on equity	n/a
Analyst coverage	Low
Last updated	19 Dec 2024

Recent future growth updates

Recent updates

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Sep 19

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Nov 05

Earnings and Revenue Growth Forecasts

NasdaqCM:APVO - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	7	-15	N/A	N/A	1
12/31/2026	N/A	-21	N/A	N/A	1
12/31/2025	N/A	-21	N/A	N/A	1
12/31/2024	N/A	-23	N/A	N/A	1
9/30/2024	N/A	-24	-23	-23	N/A
6/30/2024	N/A	-25	-24	-24	N/A
3/31/2024	N/A	-27	-23	-23	N/A
12/31/2023	N/A	-19	-12	-12	N/A
9/30/2023	N/A	-18	-12	-12	N/A
6/30/2023	N/A	-19	-13	-13	N/A
3/31/2023	N/A	17	-11	-11	N/A
12/31/2022	3	7	-21	-21	N/A
9/30/2022	7	6	-19	-19	N/A
6/30/2022	10	6	-17	-17	N/A
3/31/2022	13	-30	-20	-19	N/A
12/31/2021	12	-29	-22	-22	N/A
9/30/2021	11	-30	-25	-24	N/A
6/30/2021	9	-30	-27	-26	N/A
3/31/2021	7	-29	-26	-26	N/A
12/31/2020	4	-31	-29	-29	N/A
9/30/2020	2	-33	-28	-28	N/A
6/30/2020	0	-37	-28	-28	N/A
3/31/2020	N/A	-41	-40	-40	N/A
12/31/2019	N/A	-43	-43	-42	N/A
9/30/2019	6	-48	-45	-45	N/A
6/30/2019	12	-49	-49	-48	N/A
3/31/2019	19	-52	-49	-48	N/A
12/31/2018	23	-54	-52	-51	N/A
9/30/2018	20	-49	-61	-60	N/A
6/30/2018	20	-34	N/A	-50	N/A
3/31/2018	17	-35	N/A	-47	N/A
12/31/2017	15	-33	N/A	-42	N/A
9/30/2017	15	-39	N/A	-33	N/A
6/30/2017	11	-115	N/A	-31	N/A
3/31/2017	4	-119	N/A	-35	N/A
12/31/2016	10	-120	N/A	-37	N/A
9/30/2016	15	-122	N/A	-38	N/A
6/30/2016	19	-61	N/A	-47	N/A
3/31/2016	30	-61	N/A	-47	N/A
12/31/2015	34	-59	N/A	-49	N/A
12/31/2014	46	-51	N/A	-47	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: APVO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APVO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APVO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: APVO is forecast to have no revenue next year.

High Growth Revenue: APVO is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if APVO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/23 11:36
End of Day Share Price	2025/01/23 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aptevo Therapeutics Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Wangzhi Li	Ladenburg Thalmann & Company
Edward Tenthoff	Piper Sandler Companies
Jonathan Aschoff	Roth Capital Partners

Aptevo Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 49% to US$671

Price target decreased by 33% to US$12.00

Consensus forecasts updated

Price target decreased to US$18.00

Consensus forecasts updated

Consensus revenue estimates fall by 15%

Recent updates

New minor risk - Profitability

Aptevo Therapeutics Inc. Announces 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline Aml Trial

Aptevo Therapeutics Inc. Announces Bispecific Antibody, Apvo442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split as Part of Nasdaq Compliance Plan

Aptevo Therapeutics Expands on the Potential of Mipletamig

Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2.999493 million.

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Aptevo Therapeutics Inc. Announces That Phase 1B/2 "Rainier" Frontline Acute Myeloid Leukemia (Aml) Trial Initiated

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Nasdaq Listing Rule 5550(a)(2)

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2 million.

Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024

Price target increased by 49% to US$671

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $4.589753 million.

Aptevo Therapeutics Inc. Provides Pipeline Update

New major risk - Share price stability

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Aptevo Therapeutics Announces 1-For 44 Reverse Stock Split as Part of Nasdaq Compliance Plan

New major risk - Revenue and earnings growth

Aptevo Therapeutics Receives Non-Compliance Letter from the Staff of the Nasdaq Stock Market

New minor risk - Profitability

Price target decreased by 33% to US$12.00

Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AML

New major risk - Shareholder dilution

New major risk - Market cap size

Full year 2022 earnings: EPS exceeds analyst expectations

Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate (CBR) in Venetoclax Treatment Naïve AML Patients

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to US$18.00

Insufficient new directors

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

Consensus revenue estimates fall by 15%

Price target decreased to US$52.50

Insufficient new directors

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq

Aptevo Therapeutics Inc. Announces A Clinical Update for the Phase 1B Expansion Trial Evaluating Apvo436 in the Treatment of Acute Myeloid Leukemia

Third quarter 2021 earnings released: US$1.45 loss per share (vs US$2.15 loss in 3Q 2020)

Price target decreased to US$59.50

Insufficient new directors

Tang Capital Partners, LP along with Tang Capital Management, LLC cancelled the acquisition of remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) on June 21, 2021.

Tang Capital Withdraws its Proposals to Aptevo Therapeutics

Aptevo Therapeutics Inc. Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults with Relapsed Acute Myeloid Leukemia

Aptevo meets primary endpoint in early-stage trial for blood cancer therapy

Aptevo Therapeutics, Inc. Enters into an Llc Purchase Agreement with Medexus Pharma, Inc

Aptevo Therapeutics Inc. Expands its ADAPTIR Bispecific Platform Technology to Include a New Multi-Specific Platform Technology, ADAPTIR-FLEX

Aptevo: Positive Early Stage Data Makes This Highly Interesting

Tang Capital Partners, LP along with Tang Capital Management, LLC made a bid to acquire remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) for approximately $120 million.

Aptevo gets $50/share takeout offer from shareholder Tang

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts